Management of hyponatraemia in older people: Old threats and new opportunities

Therapeutic Advances in Drug Safety

Volumn 2, Issue 1, 2011, Pages 9-17

  Soiza, Roy L ^a   Talbot, Hannah S c ^b  

^a WOODEND HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

arginine vasopressin; elderly; hyponatraemia; syndrome of inappropriate antidiuretic hormone; tolvaptan; vasopressin receptor antagonist

Indexed keywords

EID: 84993660884     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098610394233     Document Type: Review

References (59)

1. Aaseth J.O. Tangen M.K. Beitnes J.O. (2001) Hyponatraemic emergency – a serious effect of thiazide treatment in the elderly. Tidsskr Nor Laegeforen 121: 921–923.
2. Adrogue H.J. Madias N.E. (2000) Hyponatraemia. N Engl J Med 342: 1581–1589.
3. Arieff A.I. Llach F. Massry S.G. (1976) Neurological manifestations of morbidity of hyponatremia: Correlation with brain water and electrolytes. Medicine 55: 121–129.
4. Baron D. Hutchinson T.A. (2005) The outcome of hyponatraemia in a general hospital population. Q J Med 98: 620–621.
5. Battison C. Andrews P.J. Graham C. Petty T. (2005) Randomized, controlled trial on the effect of 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 33: 196–200.
6. Baylis P.H. Heath D.A. (1978) Water disturbances in patients treated with oral lithium carbonate. Ann Intern Med 88: 607–609.
7. Berl T. Quittnat-Pelletier F. Verbalis J.G. Schrier R.W. Bichet D.G. Ouyang J. (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21: 705–712.
8. Cawley M.J. (2007) Hyponatraemia: current treatment strategies and the role if vasopressin antagonists. Ann Pharmacol 41: 840–850.
9. Chua M. Hoyle G.E. Soiza R.L. (2007) Prognostic implications of hyponatraemia in elderly hospitalized patients. Arch Gerontol Geriatr 45: 253–258.
10. Clayton J.A. Le Jeune I.R. Hall I.P. (2006) Severe hyponatraemia in medical in-patients: Aetiology, assessment and outcome. Q J Med 99: 505–511.
11. Curtis N.J. van Heyningen C. Turner J.J. (2002) Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatraemia. Age Ageing 31: 151–153.
12. Decaux G. (2001) Long term treatment of patients with inappropriate antidiuretic hormone secretion by the vasopressin receptor antagonist, urea or furosemide. Am J Med 110: 582–584.
13. Gankam Kegne F. Andres C. Sattar L. Melot C. Decaux G. (2008) Mild hyponatremia and risk of fracture in the ambulatory elderly. Q J Med 101: 583–588.
14. Ghali J.K. Koren M.J. Taylor J.R. Brooks-Asplund E. Fan K. Long N.A. (2006) Efficacy and safety of oral conivaptan: A V1a /V2 vasopressin receptor antagonist assessed in randomized, placebo-controlled trial in patients with euvolemic or hypovolemic hyponatremia. J Clin Endocrinol Metabol 91: 2145–2152.
15. Gheorghiade M. Gottlieb S.S. Udelson J.E. Konstam M.A. Czerwiec F. Ouyang J. (2006) Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Med 97: 1064–1067.
16. Gill G. Huda B. Boyd A. Skagen K. Wile D. Watson I. (2006) Characteristics and mortality of severe hyponatraemia – a hospital based study. Clin Endocrinol 65: 246–249.
17. Gross P. (2008) Treatment of hyponatraemia. Intern Med 47: 885–891.
18. Gross P. Reimann D. Neidel J. (1998) The treatment of severe hyponatraemia. Kidney Int 64: S6–S11.
19. Hannon M.J. Thompson C.J. (2010) The syndrome of inappropriate antidiuretic hormone: Prevalence, causes and consequences. Eur J Endocrin 162: S5–S12.
20. Hantman D. Rossier B. Zohlman R. Schrier R. (1973) Rapid correction of hyponatraemia in the syndrome of inappropriate antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med 78: 780–785.
21. Heinrich S. Rapp K. Rissmann U. Becker C. Konig H.H. (2010) Cost of falls in old age: A systematic review. Osteoporosis Int 21: 891–902.
22. Hew-Butler T.D. Sharwood K. Collins M. Speedy D. Noakes T. (2006) Sodium supplementation is not required to maintain serum sodium concentrations during an Ironman triathlon. Br J Sports Med 40: 255–259.
23. Hoorn E.J. Lindemans J. Zieste R. (2006) Acute and concomitant deterioration of hyponatraemia and renal dysfunction associated with heart and liver failure. Clin Nephrol 65: 248–255.
24. Hoyle G.E. Chua M. Soiza R.L. (2006) Prevalence of hyponatremia in elderly patients. J Am Geriatr Soc 54: 1473–1473.
25. Hoyle G.E. Chua M. Soiza R.L. (2010) Volaemic assessment of the elderly hyponatraemic patient: Reliability of clinical assessment and validation of bioelectrical impedance analysis. Q J Med 7 September (Epub ahead of print).
26. Huda M.S. Boyd A. Skagen K. Wile D. van Heyningen C. Watson I. (2006) Investigation and management of severe hyponatraemia in a hospital setting. Postgrad Med J 82: 216–219.
27. Konstam M.A. Gheorghiade M. Burnett J.C. Jr Grinfeld L. Maggioni A.P. Swedberg K. (2007) Effect of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297: 1319–1331.
28. Kumar S. Berl T. (1998) Sodium. Lancet 352: 220–228.
29. Luengo-Fernande R. Leal J. Gray A. (2010) Dementia 2010: The economic burden of dementia and associated research in the United Kingdom. Alzheimer–s Research Trust: Oxford.
30. Miller M. (2006) Hyponatremia and arginine vasopressin dysregulation: Mechanisms, clinical consequences, and management. J Am Geriatr Soc 54: 345–353.
31. Miller M. Morley J.E. Rubenstein L.Z. (1995) Hyponatremia in a nursing home population. J Am Geriatr Soc 43: 1410–1413.
32. Moritz L. Ayus J.C. (2010) 100 cc 3% sodium chloride bolus: A novel treatment for hyponatraemic encephalopathy. Metabol Brain Dis 25: 91–96.
33. Nielsen J. Hoffert D.J. Knepper M.A. Agre P. Nielsen S. Fenton R.A. (2008) Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: Mechanisms of aquaporin-2 dwon-regulation and cellular proliferation. Proc Nat Acad Sci U S A 105: 3634–3639.
34. Nzerue C.M. Baffoe-Bonnie H. You W. Falana B. Dai S. (2003) Predictors of outcome in hospitalized patients with severe hyponatraemia. J Natl Med Assoc 95: 335–343.
35. Renneboog B. Musch W. Vandemergel X. Manto M.U. DeCaux G. (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119: 71–78.
36. Rutan G.H. Hermanson B. Bild D.E. Kittner S.J. LaBaw F. Tell G.S. (1992) Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 19: 508–519.
37. Saito T. Ishikawa S. Abe K. Kamoi K. Yamada K. Shimizu K. (1997) Acute aquaresis by the non-peptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate antidiuretic hormone (SIADH). J Clin Endocrinol Metabol 82: 1054–1057.
38. Schrier R.W. Gross P. Gheorghiade M. Berl T. Verbalis J.G. Czerwiec F.S. (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099–2112.
39. Shapiro D.S. Sonnenblick M. Galperin I. Melkonyan L. Munter G. (2010) Severe hyponatraemia in elderly hospitalised patients: prevalence, aetiology and outcome. Intern Med J 40: 574–580.
40. Sherlock M. Thompson C.J. (2010) The syndrome of inappropriate antidiuretic hormone: Current and future management options. Eur J Endocrinol 162: S13–S18.
41. Shoaf S.E. Bramer S.L. Bricmont P. Zimmer C.A. (2007) Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrocholorothiazide. J Cardiovasc Pharmacol 50: 213–222.
42. Smith D. Moore K. Tormey W. Baylis P.H. Thompson C.J. (2004) Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrin Metabol 287: E1019–E1023.
43. Snell D.M. Bartley C. (2008) Osmotic demyelination syndrome following rapid correction of hyponatraemia. Anaesthesia 63: 92–95.
44. Soiza R.L. Hoyle G.E. (2010) The syndrome of appropriate antidiuretic hormone: Difficulties with diagnosing SIADH in older people. Intern Med J (in press).
45. Soiza R.L. Hoyle G.E. Chua M.P.W. (2008) Electrolyte and salt disturbances in older people: Causes, management and implications. Rev Clin Gerontol 18: 143–158.
46. Soupart A. Gross P. Legros J.J. Alfodi S. Annane D. Heshmati H.M. (2006) Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone with salvaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1: 1154–1160.
47. Soupart A. Decaux G. (1996) Therapeutic recommendations for management of severe hyponatremia: Current concept on pathogenesis and prevention of neurologic complications. Clin Nephrol 46: 149–169.
48. Sterns R.H. Cappucio J.D. Silver S.M. (1994) Neurologic sequelae after treatment of severe hyponatremia: A multicentre perspective. J Am Soc Nephrol 8: 1522–1530.
49. Sterns R. Nigwekar S.U. Hix J.K. (2009) The treatment of hyponatremia. Semin Nephrol 29: 282–299.
50. Thibonnier M. Conarty D.M. Preston J.A. Wilkins P.L. Berti-Mattera L.N. Mattera R. (1998) Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 449: 251–276.
51. Thompson C.J. (2010) Hyponatraemia: New associations and new treatments. Eur J Endocrin 162: S1–S3.
52. Upadhyay A. Jaber B.L. Madias N.E. (2006) Incidence and prevalence of hyponatremia. Am J Med 119: S30–S35.
53. Verbalis J.G. Goldsmith S.R. Greenberg A. Schrier R. Sterns R.H. (2007) Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med 120: S1–S21.
54. Verbalis J.G. Barsony J. Sugimura Y. Tian Y. Adams D.J. Carter E.A. (2009) Hyponatremia-induced osteoporosis. J Bone Mineral Res 25: 554–563.
55. Walkar S.S. Mount D.B. Curhan G.C. (2009) Mortality after hospitalization with mild, moderate and severe hyponatremia. Am J Med 122: 679–686.
56. Waller D.G. Edwards J.G. Papasthatis-Papayanni S. (1988) A longitudinal assessment of renal function during treatment with lithium. Q J Med 65: 553–558.
57. Ware J.E. Kosinski M. Keller S.D. (1995) SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales, 2nd. Boston Health Institute: New England Medical Center.
58. Wong F. Blei A.T. Blendis L.M. Thuluvath P.J. (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37: 182–191.
59. Zietse R. Lubbe N. Hoorn E. (2009) Current and future treatment options in SIADH. NDT Plus 2: iii12–iii19.